Claims for Patent: 7,847,061

Summary for Patent: 7,847,061

Title:	Treatment of short bowel syndrome patients with colon-in-continuity
Abstract:	Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Inventor(s):	Sanguinetti; Elizabeth Lemaire (Salt Lake City, UT), Marriott; Thomas B. (Sandy, UT), Lopansri; Jennifer (Salt Lake City, UT), Blosch; Consuelo Maria (Mercer Island, WA)
Assignee:	NPS Pharmaceuticals, Inc. (Bedminster, NJ)
Application Number:	11/262,980
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,847,061
Patent Claims:	1. A method for enhancing intestinal absorption in a patient with short bowel syndrome presenting with colon in continuity with remnant small intestine, comprising the steps of selecting for treatment a short bowel syndrome patient presenting with colon in continuity with remnant small intestine, and treating said patient with a GLP-2 receptor agonist using a dosing regimen effective to enhance intestinal absorption by said patient, wherein said GLP-2 receptor agonist is selected from the group consisting of a GLP-2 peptide, a GLP-2 analog, a derivatized GLP-2 peptide or a derivatized GLP-2 analog. 2. A method according to claim 1, wherein said patient has at least 25% colon in continuity with remnant small intestine. 3. A method according to claim 2, wherein said patient has at least 50% colon in continuity with remnant small intestine. 4. A method according to claim 3, wherein said patient has at least 75% colon in continuity with remnant small intestine. 5. A method according to claim 1, wherein said patient has colon sufficient to produce endogenous GLP-2 plasma levels of at least 5 pmol/L in the fed state. 6. A method according to claim 5, wherein said patient has colon sufficient to produce endogenous GLP-2 plasma levels of at least 10 pmol/L in the fed state. 7. A method according to claim 1, wherein said remnant small intestine has a length of at least 25 cm. 8. A method according to claim 7, wherein said remnant small intestine has a length of at least 50 cm. 9. A method according to claim 1, wherein said enhancement of intestinal absorption is a decrease in fecal wet weight. 10. A method according to claim 1, wherein said enhancement of intestinal absorption is an increase in urine wet weight. 11. A method according to claim 1, wherein said dosing regimen comprises daily administration of said GLP-2 receptor agonist. 12. A method according to claim 1, wherein said dosing regimen comprises administration of said GLP-2 receptor agonist over a period of at least 21 days. 13. A method according to claim 1, wherein said GLP-2 receptor agonist is a mammalian GLP-2. 14. A method according to claim 13, wherein said GLP-2 receptor agonist is human GLP-2 . 15. A method according to claim 1, wherein said GLP-2 receptor agonist is a GLP-2 analog. 16. A method according to claim 15, wherein said GLP-2 receptor agonist is a human GLP-2 analog. 17. A method according to claim 15, wherein said GLP-2 receptor agonist is [Gly2]hGLP-2. 18. A method according to claim 11, wherein said GLP-2 receptor agonist is administered at a daily dose of from 5 to 500 ug/kg/day.